Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ifinatamab deruxtecan by Daiichi Sankyo for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....
Valemetostat by Daiichi Sankyo for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
Ifinatamab deruxtecan by Daiichi Sankyo for Small-Cell Lung Cancer: Likelihood of Approval
Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Small-Cell Lung Cancer. According to...
Patritumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Patritumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Breast Cancer. According to...
Datopotamab deruxtecan by Daiichi Sankyo for Metastatic Biliary Tract Cancer: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Biliary Tract Cancer. According...
Datopotamab deruxtecan by Daiichi Sankyo for Bladder Cancer: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Bladder Cancer. According to GlobalData,...
Datopotamab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Human Epidermal Growth Factor Receptor...
Trastuzumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Trastuzumab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Pre-Registration for Human Epidermal Growth Factor Receptor 2...
Datopotamab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Pre-Registration for Human Epidermal Growth Factor Receptor 2...
Datopotamab deruxtecan by Daiichi Sankyo for Non-Small Cell Lung Cancer: Likelihood of Approval
Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to...
Trastuzumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval
Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Metastatic Breast Cancer. According to...
Valemetostat by Daiichi Sankyo for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
Ifinatamab deruxtecan by Daiichi Sankyo for Small-Cell Lung Cancer: Likelihood of Approval
Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Small-Cell Lung Cancer. According to...
Patritumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Patritumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval
Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Breast Cancer. According to...
Esaxerenone by Daiichi Sankyo for Diabetic Hypertension: Likelihood of Approval
Esaxerenone is under clinical development by Daiichi Sankyo and currently in Phase II for Diabetic Hypertension. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Daiichi Sankyo's Datopotamab deruxtecan?
Datopotamab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Pre-Registration program in Non-Small Cell Lung...
Risk adjusted net present value: What is the current valuation of Daiichi Sankyo's Raludotatug Deruxtecan?
Raludotatug Deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Phase I program in Renal Cell...